Case SC5 carried a TP53-mutant clone with loss of heterozygosity, which had substantially expanded at the time of AML diagnosis and expanded further at the time of relapse after treatment with venetoclax and 5-azacitidine, whereas the other clones had disappeared (Fig. 6f). This evidence concerns the gene TP53 and acute myeloid leukemia.